Literature DB >> 20004935

Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases.

Marlo M Nicolas1, Pheroze Tamboli, Jose A Gomez, Bogdan A Czerniak.   

Abstract

In this article, we supplement the few published articles by describing the clinical and pathologic features of pleomorphic and dedifferentiated leiomyosarcoma from 41 patients (27 women and 14 men) with an age range of 25 to 75 years (mean, 56.5 years), representing the largest cohort reported to date. The typical leiomyosarcoma component accounted for <5% to 60% (mean, 15%) of the tumor. The pleomorphic sarcoma component was composed of polygonal cells in 57% of cases, spindle cells in 21%, a combination of polygonal, epithelioid, rhabdoid, and/or spindle cells in 18%, and predominantly epithelioid cells in 3%. The classical leiomyosarcoma component was positive for at least one myogenic immunohistochemical marker in 29 tumors tested; smooth muscle actin in 100% (27/27), calponin in 90% (9/10), muscle-specific actin in 90% (10/11), desmin in 86% (23/27), smooth muscle myosin heavy chain (SMMS-1) in 67% (4/6), and caldesmon in 57% (4/7). The pleomorphic sarcoma component was reactive for at least one muscle marker in 77% (23/30) of cases; smooth muscle actin in 63% (17/27), calponin in 60% (6/10), SMMS-1 in 60% (3/5), desmin in 59% (16/27), muscle-specific actin in 40% (4/10), and caldesmon in 29% (2/7). The classical leiomyosarcoma component was often strongly positive for myogenic markers, and the pleomorphic sarcoma component usually showed focal and less intense immunoreactivity. Based on staining for muscle markers in the pleomorphic component, twenty-three cases were designated as pleomorphic leiomyosarcoma, and 7 cases were designated as dedifferentiated leiomyosarcoma (negative for all muscle markers used). Eleven cases, in which tissue was not available for immunhistochemical stains, the question of pleomorphic versus dedifferentiated leiomyosarcoma could not be answered. The incidence of metastasis was 89% (32/36) and the mortality rate was 50% (18/36) at last follow-up (3-104 months; mean, 27.5 months). Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004935     DOI: 10.1016/j.humpath.2009.10.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  21 in total

1.  Primary cardiac leiomyosarcoma presenting as haemoptysis in a 22-year-old patient: an unusual presentation of a rare condition.

Authors:  Masroor Hassan; Maria Khattak; Hafez Mohammad Ammar Abdullah; Bushra Nasib
Journal:  BMJ Case Rep       Date:  2017-07-13

Review 2.  [Pleomorphic high-grade soft tissue sarcomas: is the subclassification up to date?].

Authors:  G Mechtersheimer; M Renner; R Penzel; P Schirmacher
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

3.  Recurrent renal leiomyosarcoma mimicking a colonic submucosal tumor: a case report.

Authors:  Yun Jeung Kim; Hee Seok Moon; Eaum Seok Lee; Jae Kyu Sung; Hyun Yong Jeong; Ji Yeon Kim; Dae Young Kang
Journal:  J Korean Soc Coloproctol       Date:  2011-10-31

4.  Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas.

Authors:  Wei Tian; Guowen Wang; Jilong Yang; Yi Pan; Yulin Ma
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 5.  Pleomorphic leiomyosarcoma with a dedifferentiation-like appearance in the kidney: case report and literature review.

Authors:  Shogo Tajima; Michihiko Waki; Masashi Fukuyama
Journal:  Med Mol Morphol       Date:  2015-04-25       Impact factor: 2.309

6.  Pleomorphic Liposarcoma Arising in a Lipoleiomyosarcoma of the Uterus: Report of a Case With Genetic Profiling by a Next Generation Sequencing Panel.

Authors:  J Kenneth Schoolmeester; Michael D Stamatakos; Ann M Moyer; Kay J Park; Melissa Fairbairn; Amanda N Fader
Journal:  Int J Gynecol Pathol       Date:  2016-07       Impact factor: 2.762

7.  Leiomyosarcoma of Mandible: A Diagnostic Dilemma; Case Report and Review of Literature.

Authors:  Mihika Bala; Amit Ray; Ankita Saraf
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-01-21

8.  Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Authors:  Elizabeth G Demicco; Genevieve M Boland; Kari J Brewer Savannah; Kristelle Lusby; Eric D Young; Davis Ingram; Kelsey L Watson; Marshall Bailey; Xiangqian Guo; Jason L Hornick; Matt van de Rijn; Wei-Lien Wang; Keila E Torres; Dina Lev; Alexander J Lazar
Journal:  Histopathology       Date:  2015-01-12       Impact factor: 5.087

9.  ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.

Authors:  Lucie Darmusey; Gaëlle Pérot; Noémie Thébault; Sophie Le Guellec; Nelly Desplat; Laëtitia Gaston; Lucile Delespaul; Tom Lesluyes; Elodie Darbo; Anne Gomez-Brouchet; Elodie Richard; Jessica Baud; Laura Leroy; Jean-Michel Coindre; Jean-Yves Blay; Frédéric Chibon
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

10.  The prognostic role of PRUNE2 in leiomyosarcoma.

Authors:  Lin-Ru Zhao; Wei Tian; Guo-Wen Wang; Ke-Xin Chen; Ji-Long Yang
Journal:  Chin J Cancer       Date:  2013-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.